AN2 Therapeutics, Inc. (ANTX) Stock Grade

About AN2 Therapeutics, Inc.'s fundamentals

AN2 Therapeutics is a pre-revenue or early-stage biotechnology company with a market capitalization of $34.4 million. The company reported zero revenue growth year-over-year and generated no net profit, instead posting a net loss in its latest annual statement. Traditional valuation metrics like P/E ratio and return on equity are not meaningful due to the company's current financial position. As a clinical-stage biotech firm, AN2 Therapeutics' financial performance is typical for companies focused on drug development rather than commercialized products.